跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
ZEPOSIA
Authorized
STANDARD
ZEPOSIA
bristol-myers squibb canada
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
6b800e5aeca1ae75
Company
bristol-myers squibb canada
Type
Standard
Approval Details
Approval Id
6b800e5aeca1ae75
Drug Approval Canada Name
ZEPOSIA
Product Name
ZEPOSIA
Status
Marketed
Status Date
2024-09-03
Original Market Date
2020-11-12
Din
02505991
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
90:04.16
Atc Original
L04AE02 OZANIMOD
Atc Name
l 04 ae 02
Aig Number
0162518003
Company Name
bristol-myers squibb canada
Company Address
2344 Boul. Alfred-Nobel, Suite 300, St-Laurent, Quebec, Canada, H4S 0A4
Active Ingredients
OZANIMOD (OZANIMOD HYDROCHLORIDE)
0.92 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
6b800e5aeca1ae75
Type
Standard
Back to Health Canada Approvals
ZEPOSIA - Health Canada Drug Approval Details